What are the different types of thyroid cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Types of Thyroid Cancer

Thyroid cancer is classified into three main histologic categories: differentiated thyroid carcinoma (including papillary, follicular, and Hürthle cell), medullary carcinoma, and anaplastic carcinoma, with papillary being by far the most common at 89% of cases. 1

Major Histologic Categories

1. Differentiated Thyroid Carcinoma (DTC)

Papillary Thyroid Carcinoma (PTC)

  • Accounts for approximately 89% of all thyroid cancers, making it the predominant type 1
  • Carries an excellent prognosis with 5-year survival rates of 98% for stages I-III 1
  • 10-year survival rates reach 93-99% in the general population 2
  • Arises from follicular cells of the thyroid 2
  • Typically presents as a cold nodule on imaging 3

Follicular Thyroid Carcinoma (FTC)

  • Represents 5.1% of thyroid cancers 1
  • Has a 5-year survival rate of 90% for stages I-III 1
  • 10-year survival is approximately 85% 4
  • Also arises from follicular cells and presents as a cold nodule 3

Hürthle Cell Carcinoma (HCC)

  • Comprises 2.2-3% of all thyroid carcinomas 1, 4
  • Has a 10-year survival rate of approximately 76%, which is notably lower than papillary and follicular types 4
  • Classified as a distinct subtype of differentiated thyroid cancer by the World Health Organization 4
  • Defined as "pure" when Hürthle cell component exceeds 75% of the tumor 4
  • Presents most commonly as a solitary cold nodule 4, 3

2. Medullary Thyroid Carcinoma (MTC)

  • Accounts for 1.7-4% of thyroid cancers 1, 2
  • Arises from parafollicular C-cells, not follicular epithelium 2
  • Has a 10-year survival rate of 60-70% 5
  • Presents as a cold nodule 3
  • Associated with RET mutations and can be part of Multiple Endocrine Neoplasia type 2 (MEN2) syndrome 5

3. Anaplastic Thyroid Carcinoma (ATC)

  • Represents only 0.8% of thyroid cancers but is the most aggressive type 1
  • Classified as an aggressive undifferentiated tumor 1
  • Has a dismal prognosis with 5-year survival rate of only 7% 1
  • Most patients die within 6 months of diagnosis 6
  • Presents as a cold nodule 3

Clinical Significance and Prognostic Implications

The dramatic difference in survival rates between differentiated and undifferentiated thyroid cancers underscores the critical importance of accurate histologic classification for treatment planning and prognostic counseling. 1

Key Epidemiologic Patterns

  • Thyroid cancer is 2-4 times more common in women than men across all histologic types 1
  • The incidence has been increasing globally, primarily due to detection of small papillary carcinomas (<1 cm) through improved imaging 1
  • Despite rising incidence, mortality from thyroid cancer has declined over recent decades 1

Important Clinical Pitfalls

Common Pitfall: Treating Hürthle cell carcinoma with lobectomy alone is inadequate, as this subtype requires total thyroidectomy due to its more aggressive behavior compared to other differentiated thyroid cancers 4

Diagnostic Challenge: Molecular diagnostics are specifically not recommended for Hürthle cell neoplasms due to high false-positive rates (86% unnecessary surgery rate historically), though newer tests show improved performance 4

Critical Distinction: Medullary thyroid carcinoma arises from C-cells rather than follicular epithelium, which means it does not respond to TSH suppression therapy or radioactive iodine—treatments that are standard for differentiated thyroid cancers 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Mounjaro Safety in Thyroid Cancer History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

TSH Derangement in Thyroid Cancers and Nodules

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hürthle Cell Thyroid Carcinoma Treatment and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Thyroid disorders. Part III: neoplastic thyroid disease.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2006

Research

Predictors of thyroid tumor aggressiveness.

The Western journal of medicine, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.